$1.24
▼ -3.9% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering
Overview
52-week range
$1.02
$1.88
26% of range
Avg surprise (last 3)
+6.7%
Avg reaction (last 2)
+1.0%
50% positive
Latest IV / EM
1271%
EM ±205.6% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.34 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.34 | $-0.41 | +17.1% | 0.0% | +2.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.40 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.41 | $-0.39 | -5.1% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.34 | $-0.37 | +8.1% | — | -0.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.37 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.02 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.30 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.34 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.42 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-19M | $-19M | — | $-23M | $-23M | $-22M | — | $-22M |
| Net income | $-18M | $-18M | — | $-21M | $-21M | $-17M | — | $-19M |
| EPS (diluted) | $-0.34 | $-0.34 | — | $-0.40 | $-0.41 | $-0.34 | — | $-0.37 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12M | $39M | $38M | $36M | $44M | $51M | $41M | $49M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $81M | $96M | $115M | $132M | $145M | $163M | $176M | $190M |
| Total assets | $82M | $97M | $117M | $134M | $153M | $171M | $191M | $223M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $9M | $12M | $13M | $12M | $11M | $15M | $26M |
| Total equity | $72M | $88M | $105M | $121M | $141M | $160M | $176M | $198M |